风湿科医生对口服双膦酸盐治疗的管理及治疗变更的决定因素:一项基于病例 vignette 的研究
该研究采用病例 vignette 方法,纳入 142 名风湿科医生,评估口服双膦酸盐的治疗模式及治疗变更的决定因素。结果显示仅 4.2% 的患者在 5 年时维持同一治疗,每次随访有 20-30% 的病例发生停药或换药。治疗依从性、血清 CTX 值、身高变化和新发椎体骨折是显著的决定因素。
要点
- 仅 4.2% 的患者在 5 年时维持口服双膦酸盐治疗,每次随访 20-30% 的病例发生停药或换药。
- 临床检查、身高测量、跌倒询问和治疗依从性在超过 90% 的病例中被认为必要。
- 治疗依从性、血清 CTX 值、身高变化和新发椎体骨折是治疗变更的显著决定因素。
核心结论
- 由风湿科医生管理的绝经后女性中,口服双膦酸盐的维持率低,治疗变更的决定因素少,更多关于适当随访的信息可能有助于患者管理。
研究设计与样本
- 采用病例 vignette 方法,142 名风湿科医生参与,呈现三个基线临床 vignette,共评估 426 个虚拟临床病例。
主要发现
- 临床检查、患者身高、跌倒询问和治疗依从性在超过 90% 的病例中被认为必要。
- 骨密度在 2 年、3 年和 5 年时分别有 22%、40% 和 71% 的病例被测量。
- 牙科随访在不到 25% 的病例中被推荐。
- 仅 4.2% 的患者在 5 年时维持同一治疗,每次随访有 20-30% 的病例发生治疗变更(停药或换药)。
- 显著的决定因素包括治疗依从性、血清 1 型胶原 C 端交联端肽(CTX)值、患者身高变化和新发椎体骨折的发生。
关键数值与推荐
- 临床检查、患者身高、跌倒询问和治疗依从性在超过 90% 的病例中被认为必要。
- 骨密度测量率在 2 年、3 年和 5 年分别为 22%、40% 和 71%。
- 牙科随访推荐率低于 25%。
- 5 年时维持同一治疗的患者比例为 4.2%。
- 每次随访治疗变更(停药或换药)的发生率为 20-30%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Using case vignette methodology, this study shows that only 4% of patients are maintained on oral bisphosphonates over 5 years, and prescribers switch or stop the treatment in 20-30% of cases at each visit. There are few determinants of these changes. More information on appropriate follow-up could help in patients' management. INTRODUCTION: Persistence to oral bisphosphonates, the most commonly prescribed anti-osteoporotic treatments, is low. The aim of this study was to evaluate the role of rheumatologists on the treatment patterns, and to assess the determinants of treatment changes. METHODS: We used the methodology of case vignettes with the participation of 142 rheumatologists. Three baseline clinical vignettes were presented: (1) the physician was asked to indicate the most appropriate period to schedule the next visit over 5 years, (2) the physician was tested about parameters for follow-up (including traps), and (3) various results (both clinical, biological, densitometric, and radiological) were given by random and analyzed as determinants of treatment changes. RESULTS: The study allowed assessment of 426 virtual clinical cases. Clinical examinations, patient's height, inquiries about falls, and adherence to treatment were deemed necessary in > 90% of cases. Bone mineral density was measured in 22, 40, and 71% of cases at 2, 3, and 5 years, respectively. Dental follow-up was recommended in less than 25% of cases. Only 4.2% of patients were maintained on the same treatment at 5 years, and a change of treatment (stop or switch) occurs in 20-30% of cases at each visit. Significant determinants were adherence to treatment, serum C-terminal crosslinking telopeptide of type 1 collagen (CTX) value, change in patient's height, and the occurrence of an incident vertebral fracture. CONCLUSION: Our study shows that maintenance of oral bisphosphonate in postmenopausal women managed by rheumatologists is low; there are few determinants of these changes and more information on appropriate follow-up could help in patients' management.
引用
- Roux C, Baron G, Briot K, et al. Management of oral bisphosphonates treatment by rheumatologists and determinants of therapeutic changes: a case-vignette-based study. Osteoporos Int. 2017. PMID: 28852785. doi:10.1007/s00198-017-4188-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。